ACORDA NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics Inc. To Contact The Firm

NEW YORK, April 7, 2017

The investigation focuses on whether the Company and its executives violated federal securities laws in connection with Acorda's Ampyra patents.   

On March 31, 2017, the Company announced that U.S. District Judge Leonard Stark of the United States District Court for the District of Delaware invalidated the Company's four patents under U.S. Patent Nos. 8,663,685 (the '685 patent), 8,007,826 (the '826 patent), 8,440,703 (the '703 patent), and 8,354,437 (the '437 patent), which pertain to Ampyra.  

On this news, Acorda's share price fell from $26.75 per share on March 30, 2017 to a closing price of $21.00 on March 31, 2017—a $5.75 or a 21.5% drop.

Request more information now by clicking here:  www.faruqilaw.com/ACOR. There is no cost or obligation to you.

Take Action

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Acorda's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.